CTP‐543 for the Treatment of Adults with Moderate to Severe Alopecia Areata

Last Updated:
01/18/2019
Status:
Recruiting
Country:
United States
Eligibility:
Age 18-65; diagnosed with moderate to severe alopecia areata
Drug:
CTP‐543
Administration:
Oral
Sponsor: 
Concert Pharmaceuticals, Inc.

The purpose of this study is to compare the effectiveness and tolerability of two different dosing regimens of the investigational drug, CTP-543, in adults with chronic, moderate to severe alopecia areata. Approximately 60 adults with moderate to severe alopecia areata may participate in this study at clinical trial sites throughout the United States. Read More